Explorations of clinical trials and pharmacovigilance databases of MF59 ®-adjuvanted influenza vaccines for associated cases of narcolepsy

Scandinavian Journal of Infectious Diseases

Volumn 43, Issue 9, 2011, Pages 702-706

  Tsai, Theodore F ^a   Crucitti, Antonio ^a   Nacci, Pantaleo ^a   Nicolay, Uwe ^a   Cioppa, Giovanni Della ^a   Ferguson, John ^a   Clemens, Ralf ^a  

^a Novartis Vaccines and Diagnostics Inc   (United States)

Author keywords

Adjuvanted vaccine; MF59; Narcolepsy; Pandemic vaccine; Vaccine adverse events

Indexed keywords

INFLUENZA VACCINE; MIFAMURTIDE;

2009 H1N1 INFLUENZA; ADJUVANT THERAPY; ARTICLE; CLINICAL TRIAL (TOPIC); DATA BASE; DRUG SURVEILLANCE PROGRAM; HUMAN; INFLUENZA VACCINATION; NARCOLEPSY; SYSTEMATIC REVIEW;

ADJUVANTS, IMMUNOLOGIC; HUMANS; INFLUENZA VACCINES; NARCOLEPSY; POLYSORBATES; SQUALENE;

EID: 79960827514     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2011.580777     Document Type: Article

References (17)

1. Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet 2007;369:499-511. (Pubitemid 46209316)
2. Ahmed I, Thorpy M. Clinical features, diagnosis and treatment of narcolepsy. Clin Chest Med 2010;31:371-81.
3. Dauvilliers Y, Montplaisir J, Cochen V, Desautels A, Einen M, Lin L, et al. PostH1N1 narcolepsy - cataplexy. Sleep 2010;22:1428-30.
4. World Health Organization. Global Advisory Committee on Vaccine Safety: Statement on narcolepsy and vaccination. Geneva: WHO; 2011. Available at: http://www.who.int/vaccine-safety/topics/influenza/pandemic/h1n1-safety- assessing/narcolepsy-february2011/en/(accessed 23 March 2011).
5. National Institute for Health and Welfare (THL) Finland. National narcolepsy task force interim report 31 January 2011. Helsinki, Finland: THL; 2011. Available at: http://www.thl. fi/thl-client/pdfs/dce182fb-651e-48a1-b018- 3f774d6d1875 (accessed 20 March 2011).
6. Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, et al. Adjuvant system AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011;29:2461-73.
7. The Medical Dictionary for Regulatory Activities. MedDRA web-based browser version 2010.01.01. Available at: https://www.meddrabrowser.org/ dsnavigator/(accessed 15 March 2011).
8. Dement W, Carskadon M, Ley R. The prevalence of narcolepsy II. Sleep Res 1973;2:147.
9. Dauvilliers Y, Montplaisir J, Molinari N, Carlander B, Ondze B, Besset A, et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 2001;57:2029-33. (Pubitemid 33126870)
10. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000;355:39-40. (Pubitemid 30072183)
11. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6:991-7.
12. Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469-74.
13. Cvetkovic-Lopes V, Bayer L, Dorsaz S, Maret S, Pradervand S, Dauvilliers Y, et al. Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. J Clin Invest 2010;120:713-9.
14. Hor H, Kutalik Z, Dauvilliers Y, Valsesia A, Lammers GJ, Donjacour CE, et al. Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. Nat Genet 2010;42:786-90.
15. Hallmayer J, Faraco J, Lin L, Hesselson S, Winkelmann J, Kawashima M, et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet 2009;41:708-11.
16. Kornum BR, Kawashima M, Faraco J, Lin L, Rico TJ, Hesselson S, et al. Common variants in PYRY11 are associated with narcolepsy. Nat Genet 2011;43:66-71.
17. Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. MF59-adjuvanted versus non-adjuvanted vaccines: integrated analysis from a large safety database. Vaccine 2009;27:6959-65.